← 返回

间充质干细胞来源抗菌肽作为潜在抗肿瘤药物:干细胞与外泌体抗癌机制的新认识

英文原题:Mesenchymal Stem Cell-Derived Antimicrobial Peptides as Potential Anti-Neoplastic Agents: New Insight into Anticancer Mechanisms of Stem Cells and Exosomes.

查看英文原题

Mesenchymal Stem Cell-Derived Antimicrobial Peptides as Potential Anti-Neoplastic Agents: New Insight into Anticancer Mechanisms of Stem Cells and Exosomes.

PubMed 2022/07/06(内容时间) Front Cell Dev Biol Q1 · IF 5.3(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

间充质干细胞(MSC)是成体多能细胞,具有显著再生和抗肿瘤作用,包括诱导癌细胞凋亡及降低多药耐药,因此可能成为癌症治疗替代选择。MSC可改变癌细胞行为、肿瘤微环境状态及免疫细胞活性,从而促使肿瘤消退。已观察到,在肿瘤微环境常见的炎症条件下,MSC会产生并释放具有抗肿瘤作用的抗菌肽(AMP)。这些肽可与肿瘤细胞带负电的细胞膜结合,破坏细胞膜并干扰胞内通路,发挥显著靶向抗癌效应。因此,AMP可视为MSC广泛抗肿瘤作用的一部分。本综述聚焦MSC来源AMP的潜在抗肿瘤作用及机制,也讨论预处理方法和利用外泌体增强MSC向癌细胞产生及递送AMP的策略,并探讨临床给药及其临床实践挑战。

展开英文摘要原文

Mesenchymal stem cells (MSCs), as adult multipotent cells, possess considerable regenerative and anti-neoplastic effects, from inducing apoptosis in the cancer cells to reducing multidrug resistance that bring them up as an appropriate alternative for cancer treatment. These cells can alter the behavior of cancer cells, the condition of the tumor microenvironment, and the activity of immune cells that result in tumor regression.

It has been observed that during inflammatory conditions, a well-known feature of the tumor microenvironment, the MSCs produce and release some molecules called "antimicrobial peptides (AMPs)" with demonstrated anti-neoplastic effects. These peptides have remarkable targeted anticancer effects by attaching to the negatively charged membrane of neoplastic cells, disrupting the membrane, and interfering with intracellular pathways.

Therefore, AMPs could be considered as a part of the wide-ranging anti-neoplastic effects of MSCs. This review focuses on the possible anti-neoplastic effects of MSCs-derived AMPs and their mechanisms. It also discusses preconditioning approaches and using exosomes to enhance AMP production and delivery from MSCs to cancer cells. Besides, the clinical administration of MSCs-derived AMPs, along with their challenges in clinical practice, were debated.

论文信息

作者
Moeinabadi-Bidgoli K、Rezaee M、Rismanchi H、Mohammadi MM、Babajani A
单位
Department of Pharmacology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.Iran
文献类型
综述
期刊
Frontiers in cell and developmental biology2022
原文标识
PubMed 35874827 · DOI 10.3389/fcell.2022.900418